Cargando…

Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors

The Mycobacterium tuberculosis protein MmpL3 performs an essential role in cell wall synthesis, since it effects the transport of trehalose monomycolates across the inner membrane. Numerous structurally diverse pharmacophores have been identified as inhibitors of MmpL3 largely based on the identific...

Descripción completa

Detalles Bibliográficos
Autores principales: McNeil, Matthew B., O’Malley, Theresa, Dennison, Devon, Shelton, Catherine D., Sunde, Bjorn, Parish, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565900/
https://www.ncbi.nlm.nih.gov/pubmed/33055263
http://dx.doi.org/10.1128/mSphere.00985-20
_version_ 1783596034835873792
author McNeil, Matthew B.
O’Malley, Theresa
Dennison, Devon
Shelton, Catherine D.
Sunde, Bjorn
Parish, Tanya
author_facet McNeil, Matthew B.
O’Malley, Theresa
Dennison, Devon
Shelton, Catherine D.
Sunde, Bjorn
Parish, Tanya
author_sort McNeil, Matthew B.
collection PubMed
description The Mycobacterium tuberculosis protein MmpL3 performs an essential role in cell wall synthesis, since it effects the transport of trehalose monomycolates across the inner membrane. Numerous structurally diverse pharmacophores have been identified as inhibitors of MmpL3 largely based on the identification of resistant isolates with mutations in MmpL3. For some compounds, it is possible there are different primary or secondary targets. Here, we have investigated resistance to the spiral amine class of compounds. Isolation and sequencing of resistant mutants demonstrated that all had mutations in MmpL3. We hypothesized that if additional targets of this pharmacophore existed, then successive rounds to generate resistant isolates might reveal mutations in other loci. Since compounds were still active against resistant isolates, albeit with reduced potency, we isolated resistant mutants in this background at higher concentrations. After a second round of isolation with the spiral amine, we found additional mutations in MmpL3. To increase our chance of finding alternative targets, we ran a third round of isolation using a different molecule scaffold (AU1235, an adamantyl urea). Surprisingly, we obtained further mutations in MmpL3. Multiple mutations in MmpL3 increased the level and spectrum of resistance to different pharmacophores but did not incur a fitness cost in vitro. These results support the hypothesis that MmpL3 is the primary mechanism of resistance and likely target for these pharmacophores. IMPORTANCE Mycobacterium tuberculosis is a major global human pathogen, and new drugs and new drug targets are urgently required. Cell wall biosynthesis is a major target of current tuberculosis drugs and of new agents under development. Several new classes of molecules appear to have the same target, MmpL3, which is involved in the export and synthesis of the mycobacterial cell wall. However, there is still debate over whether MmpL3 is the primary or only target for these classes. We wanted to confirm the mechanism of resistance for one series. We identified mutations in MmpL3 which led to resistance to the spiral amine series. High-level resistance to these compounds and two other series was conferred by multiple mutations in the same protein (MmpL3). These mutations did not reduce growth rate in culture. These results support the hypothesis that MmpL3 is the primary mechanism of resistance and likely target for these pharmacophores.
format Online
Article
Text
id pubmed-7565900
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-75659002020-10-27 Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors McNeil, Matthew B. O’Malley, Theresa Dennison, Devon Shelton, Catherine D. Sunde, Bjorn Parish, Tanya mSphere Research Article The Mycobacterium tuberculosis protein MmpL3 performs an essential role in cell wall synthesis, since it effects the transport of trehalose monomycolates across the inner membrane. Numerous structurally diverse pharmacophores have been identified as inhibitors of MmpL3 largely based on the identification of resistant isolates with mutations in MmpL3. For some compounds, it is possible there are different primary or secondary targets. Here, we have investigated resistance to the spiral amine class of compounds. Isolation and sequencing of resistant mutants demonstrated that all had mutations in MmpL3. We hypothesized that if additional targets of this pharmacophore existed, then successive rounds to generate resistant isolates might reveal mutations in other loci. Since compounds were still active against resistant isolates, albeit with reduced potency, we isolated resistant mutants in this background at higher concentrations. After a second round of isolation with the spiral amine, we found additional mutations in MmpL3. To increase our chance of finding alternative targets, we ran a third round of isolation using a different molecule scaffold (AU1235, an adamantyl urea). Surprisingly, we obtained further mutations in MmpL3. Multiple mutations in MmpL3 increased the level and spectrum of resistance to different pharmacophores but did not incur a fitness cost in vitro. These results support the hypothesis that MmpL3 is the primary mechanism of resistance and likely target for these pharmacophores. IMPORTANCE Mycobacterium tuberculosis is a major global human pathogen, and new drugs and new drug targets are urgently required. Cell wall biosynthesis is a major target of current tuberculosis drugs and of new agents under development. Several new classes of molecules appear to have the same target, MmpL3, which is involved in the export and synthesis of the mycobacterial cell wall. However, there is still debate over whether MmpL3 is the primary or only target for these classes. We wanted to confirm the mechanism of resistance for one series. We identified mutations in MmpL3 which led to resistance to the spiral amine series. High-level resistance to these compounds and two other series was conferred by multiple mutations in the same protein (MmpL3). These mutations did not reduce growth rate in culture. These results support the hypothesis that MmpL3 is the primary mechanism of resistance and likely target for these pharmacophores. American Society for Microbiology 2020-10-14 /pmc/articles/PMC7565900/ /pubmed/33055263 http://dx.doi.org/10.1128/mSphere.00985-20 Text en Copyright © 2020 McNeil et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
McNeil, Matthew B.
O’Malley, Theresa
Dennison, Devon
Shelton, Catherine D.
Sunde, Bjorn
Parish, Tanya
Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors
title Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors
title_full Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors
title_fullStr Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors
title_full_unstemmed Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors
title_short Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors
title_sort multiple mutations in mycobacterium tuberculosis mmpl3 increase resistance to mmpl3 inhibitors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565900/
https://www.ncbi.nlm.nih.gov/pubmed/33055263
http://dx.doi.org/10.1128/mSphere.00985-20
work_keys_str_mv AT mcneilmatthewb multiplemutationsinmycobacteriumtuberculosismmpl3increaseresistancetommpl3inhibitors
AT omalleytheresa multiplemutationsinmycobacteriumtuberculosismmpl3increaseresistancetommpl3inhibitors
AT dennisondevon multiplemutationsinmycobacteriumtuberculosismmpl3increaseresistancetommpl3inhibitors
AT sheltoncatherined multiplemutationsinmycobacteriumtuberculosismmpl3increaseresistancetommpl3inhibitors
AT sundebjorn multiplemutationsinmycobacteriumtuberculosismmpl3increaseresistancetommpl3inhibitors
AT parishtanya multiplemutationsinmycobacteriumtuberculosismmpl3increaseresistancetommpl3inhibitors